Compare BMRA & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRA | CTXR |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.4M |
| IPO Year | 1995 | 2010 |
| Metric | BMRA | CTXR |
|---|---|---|
| Price | $1.78 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.9K | ★ 178.9K |
| Earning Date | 10-15-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.81 | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,453,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $104.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.45 | $0.45 |
| 52 Week High | $3.21 | $2.19 |
| Indicator | BMRA | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 33.59 |
| Support Level | $1.50 | N/A |
| Resistance Level | $2.23 | $0.61 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 18.26 | 10.08 |
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America generating key revenue from North American Markets.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.